Capital Fund Management S.A. Novo Cure LTD Call Options Transaction History

Capital Fund Management S.A.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$12.42 - $17.29 $798,606 - $1.11 Million	-64,300 Reduced 38.73%	101,700 $1.59 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $1.63 Million - $2.32 Million	146,900 Added 769.11%	166,000 $2.48 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $308,465 - $808,885	19,100 New	19,100 $308,000
Q1 2022 May 12, 2022	SELL	$60.15 - $84.52 $1.05 Million - $1.48 Million	-17,500 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$75.08 - $121.99 $52,556 - $85,393	-700 Reduced 3.85%	17,500 $1.31 Million

Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $2.11 Million - $3.54 Million	18,200 New	18,200 $2.11 Million
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $1.61 Million - $2.47 Million	-13,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$112.16 - $174.14 $549,584 - $853,285	4,900 Added 60.49%	13,000 $2.25 Million
Q4 2019 Feb 13, 2020	SELL	$68.3 - $93.8 $922,050 - $1.27 Million	-13,500 Reduced 62.5%	8,100 $683,000
Q3 2019 Nov 13, 2019	BUY	$61.86 - $97.8 $111,348 - $176,040	1,800 Added 9.09%	21,600 $1.62 Million
Q2 2019 Aug 12, 2019	BUY	$42.22 - $63.23 $835,956 - $1.25 Million	19,800 New	19,800 $1.25 Million

278

73.2M

1.43M

832K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.76B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.